News Releases

OTCQB: INTI
PRICE:
Stock Info
Advanced Search
  • Nov 18, 2014
    Company plans to commence clinical development of SUBA®-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome

    FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – November 18, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...

  • Jun 26, 2014
    Stefan Cross, Dr. Dana Ono and Mark Watson add significant biotechnology, capital markets and public accounting expertise to HPPI’s board of directors

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 26, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers,...

  • Jun 25, 2014
    $1.5 million in proceeds to fund 2014 commencement of HPPI’s clinical development program for repurposing the approved anti-fungal drug itraconazole for the treatment of cancer, initially for the treatment of Basal Cell Carcinoma Nevus Syndrome

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 25, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers,...

  • Jan 8, 2014
    Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square, San Francisco

    TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (January 8, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...

  • Sep 10, 2013
    Acquires Exclusive U.S. Rights for use of Mayne Pharma’s SUBA™ Itraconazole for treatment of cancer

    TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (September 10, 2013) – HedgePath Pharmaceuticals, Inc. (OTCPink:HPPI) (HPPI) announced today that it has signed an exclusive Supply and License...

Show 5102550100 per page
Get Important News and Updates by Email
* Required Fields